RECURRENCE RATE OF CYSTOID MACULAR EDEMA WITH TOPICAL DORZOLAMIDE TREATMENT AND ITS RISK FACTORS IN RETINITIS PIGMENTOSA.

Abstract

PURPOSE:

To investigate the rate of the recurrence of cystoid macular edema (CME) secondary to retinitis pigmentosa (RP) after the initiation of topical dorzolamide and the recurrence risk factors.

METHODS:

We retrospectively analyzed the data of RP patients at Kyushu University Hospital. We included patients who showed a treatment response to 1.0% topical dorzolamide. The day of treatment initiation was set as the baseline. Topical dorzolamide treatment was continued during the follow-up. The recurrence of CME (defined as a >20% increase in central subfield thickness compared to previous visit, or a central subfield thickness value that exceed baseline value) was evaluated at each follow-up visit. Risk factors for RP-CME recurrence were analyzed by Cox proportional hazards modeling. A Kaplan-Meier survival analysis was used to evaluate the time to recurrent RP-CME.

RESULTS:

Forty RP-CME patients showed a treatment response to topical dorzolamide. During the mean 3.9-year follow-up, 14 patients exhibited recurrence; its rate was 15.6%, 34.7%, and 48.7% at 1, 3, and 5 years, respectively. A high baseline central subfield thickness was significantly associated with recurrent (hazard ratio 1.11, 95% CI: 1.05-1.18, P = 0.0004).

CONCLUSION:

The recurrence rate of RP-CME increased with time. A high baseline central subfield thickness value was a risk factor for recurrence.

• Authors: Shotaro Shimokawa, Yusuke Murakami, Kohta Fujiwara, Jun Funatsu, Shunji Nakatake, Yoshito Koyanagi, Masato Akiyama, Noriko Yoshida, Atsunobu Takeda, Yasuhiro Ikeda, Koh-Hei Sonoda
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 42 Issue 1 Pg. 168-173 (01 01 2022) ISSN: 1539-2864 [Electronic] United States
• PMID: 34393209 (Publication Type: Journal Article, Observational Study)

Chemical References

• Carbonic Anhydrase Inhibitors
• Sulfonamides
• Thiophenes
• dorzolamide

Topics

• Administration, Topical
• Carbonic Anhydrase Inhibitors (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Incidence
• Japan (epidemiology)
• Macula Lutea (growth & development)
• Macular Edema (drug therapy, epidemiology, etiology)
• Male
• Middle Aged
• Prospective Studies
• Recurrence
• Retinitis Pigmentosa (complications, diagnosis)
• Risk Assessment (methods)
• Risk Factors
• Sulfonamides (administration & dosage)
• Thiophenes (administration & dosage)
• Time Factors
• Tomography, Optical Coherence (methods)
• Visual Acuity